Researchers from the University of Oxford are collaborating with the Japanese pharmaceutical company, SBI Pharmaceuticals, to minimise deterioration of heart function outcomes after cardiac surgery. The Trial of δ–Aminolevulinic Acid to Enhance Myocardial Protection (TALEN) will take place across the John Radcliffe Hospital, Oxford and the Queen Elizabeth Hospital, Birmingham.
For the full story on Radcliffe Department of Medicine website